ELMD
ElectromedADocument history
Earnings documents stored for ELMD.
Investor releaseQuarter not tagged2026-05-13Electromed, Inc. (ELMD) Q3 Earnings and Revenues Top Estimates
Zacks
Electromed, Inc. (ELMD) Q3 Earnings and Revenues Top Estimates
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.21 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +34.62%. A quarter ago, it was expected that this company would post earnings of $0.27 per share when it actually produced earnings of $0.32, delivering a surprise of +18.52%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Electromed, which belongs to the Zacks Medical - Instruments industry, posted revenues of $18.58 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 4.35%. This compares to year-ago revenues of $15.68 million. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Electromed shares have lost about 11% since the beginning of the year versus the S&P 500's gain of 8.3%. While Electromed has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Electromed was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy)...
Investor releaseQuarter not tagged2026-05-13Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter
Business Wire
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Third Quarter
18% Revenue growth and strong operating leverage exceeds consensus expectations for the third quarter of fiscal 2026 NEW PRAGUE, Minn., May 12, 2026--(BUSINESS WIRE)--Electromed, Inc. ("Electromed") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three and nine months ended March 31, 2026 ("Q3 FY 2026"). Q3 FY 2026 Company Highlights Net revenues increased 18.4% to a record $18.6 million in Q3 FY 2026, from $15.7 million in the third quarter of the prior fiscal year, led by an 18.6% increase in the core homecare market. Operating income increased to a record $3.8 million, a 76.0% increase from the third quarter of the prior fiscal year, and 20.3% of net revenues. Net income was a record $3.0 million, or $0.35 per diluted share, representing an increase of 58.8%, compared to $1.9 million, or $0.21 per diluted share in the third quarter of the prior fiscal year. "I'm happy to report that Electromed has delivered its 14th consecutive quarter of year-over-year revenue and profit growth. Electromed's unique business model created to address the underserved airway clearance market is achieving the desired results we had expected," said Jim Cunniff, President and Chief Executive Officer. "We continue to make investments in our sales and fulfillment teams to drive greater prescription volumes and faster delivery of our SmartVest therapy to more patients. With 86% of covered lives in the United States now under contract and our manufacturing optimization complete, we're well-positioned to capture the opportunity in the underserved bronchiectasis market. As we look ahead, our strong operational foundation, strategic investments, and continued focus on education and awareness give us confidence in sustaining our trajectory of profitable growth." Q3 FY 2026 Results All amounts below are for the three months ended March 31, 2026, and compare to the three months ended March 31, 2025 ("Q3 FY 2025"). Net revenues grew 18.4% to $18.6 million, from $15.7 million. Revenue in our direct homecare business increased by 18.6% to $16.7 million, from $14.1 million. The increase in revenue was primarily due to an increase in direct sales representatives, increased sales representative productivity, and higher net revenues per sales representative. Throughout Q3 FY 2026, we averaged 57 homecare direct field sales r...
Investor releaseQuarter not tagged2026-05-13Electromed Inc (ELMD) Q3 2026 Earnings Call Highlights: Record Revenue Growth and Strategic ...
GuruFocus.com
Electromed Inc (ELMD) Q3 2026 Earnings Call Highlights: Record Revenue Growth and Strategic ...
This article first appeared on GuruFocus. Release Date: May 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Electromed Inc (ELMD) achieved its 14th consecutive quarter of year-over-year revenue and profit growth, with Q3 revenue reaching $18.6 million, an 18.4% increase from the previous year. The company's operating income increased by 76% to $3.8 million, showcasing strong financial performance. Electromed Inc (ELMD) maintained a strong cash position of $17 million and has no debt, indicating financial stability. The company successfully launched the 'Triple Down on Bronchiectasis' campaign, which has generated over 2 million impressions and increased awareness among clinicians. Electromed Inc (ELMD) has expanded its sales force to 62 representatives, enhancing market coverage and driving revenue growth. Despite the growth, Electromed Inc (ELMD) experienced a 40.7% decline in other revenue, indicating potential challenges in certain segments. The company faced increased SG&A expenses, rising by 7.2% due to higher salaries and compensation costs. There is a significant gap in the prescription of HFCWO therapy, with 58% of qualifying patients not receiving it, highlighting a missed opportunity. The ramp-up period for new sales representatives is four to six months, which could delay immediate productivity and revenue contributions. Electromed Inc (ELMD) slowed its stock repurchase activity in Q3 due to macro market dynamics, which may affect shareholder returns. Warning! GuruFocus has detected 7 Warning Signs with VELO. Is ELMD fairly valued? Test your thesis with our free DCF calculator. Q: Have you been adding territories or regions, or have you been splitting existing territories in half? A: Jim Kniff, President and CEO: We had about 57 reps this past quarter, and the strong performance is attributable to the reps in territory and positive tailwinds from our insurance mix. We ended the quarter with 58 reps and have since increased to 62 territories. We plan to add four to five additional reps in the next fiscal year. Q: Do you still believe Brynsupri has been a net positive for SmartVest given the increased awareness around bronchiectasis? A: Jim Kniff, President and CEO: Yes, Brynsupri has increased awareness, but bronchiectasis is chronic and irreversible. Our SmartVest is crucial for removin...
Investor releaseQuarter not tagged2026-05-13Electromed Fiscal Q3 Earnings, Revenue Rise
MT Newswires
Electromed Fiscal Q3 Earnings, Revenue Rise
Electromed (ELMD) reported fiscal Q3 earnings late Tuesday of $0.35 per diluted share, up from $0.21
TranscriptFY2026 Q32026-05-12FY2026 Q3 earnings call transcript
Earnings source - 38 paragraphs
FY2026 Q3 earnings call transcript
I would now like to turn the conference over to your host, Mike Cavanaugh, Investor Relations. You may begin.
Good afternoon. Thank you for joining the Electromed Earnings Call. Earlier today, Electromed, Inc. released financial results for the third quarter of fiscal 2026. The press release is currently available on the company's website at www.smartvest.com. Before we get started, I would like to remind everyone that some of the statements that management will make on this call are considered forward-looking statements, including statements about the company's future operating and financial results and plans. Such statements are subject to risks and uncertainties that could cause actual performance or achievements to be materially different from those projected. Any such statements represent management's expectations as of today's date. You should not place any undue reliance on those forward-looking statements, and the company does not undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise.
Please refer to the company's SEC filings for further guidance on this matter. Joining me on the call today are Jim Cunniff, Electromed's President and Chief Executive Officer, and Brad Nagel, Chief Financial Officer. As on previous calls, Jim will provide operational highlights from the quarter. Brad will then review the financials, and we will close with a question-and-answer session. With that, I will now turn the call over to Jim Cunniff, President and Chief Executive Officer of Electromed.
Good afternoon, everyone, and thank thank you for joining us today. I'm excited to share our third quarter results. Let me start with the headlines. Q3 marks our 14th consecutive quarter of year-over-year revenue and profit growth. We delivered revenue of $18.6 million, representing 18.4% growth compared to the prior year. This performance reflects the strength of our commercial execution and the growing recognition of SmartVest as the leading solution for airway clearance. Growth was broad-based across our business. Our flagship home care segment grew a robust 19%. Our distributor revenues increased 3%, driven by consistent demand from our DME partners. Hospital grew 43% over prior year and rebounded after a slow second quarter. This diversified growth demonstrates the strength of our market position and the effectiveness of our multi-channel strategy. Even more impressive is our record bottom-line performance.
Operating income increased to $3.8 million in the third quarter, a 76% increase versus prior year. Diluted earnings per share came in at $0.35, up 67% versus the prior year. From a balance sheet perspective, we maintained a strong cash position of $17 million. As you may recall, our board approved a $10 million stock repurchase authorization in the first quarter, reflecting our confidence that Electromed represents a sound investment. We slowed repurchasing activity in Q3 as we assess the recent macro market dynamics. We remain committed to finding ways to deliver value back to our shareholders. Looking at our results, it's clear that the business model Electromed has built is working well.
Our focus on airway clearance for the home care market, coupled with our productive sales and fulfillment teams, which handle the process from prescription to delivery of the vest to the patient's home, sets us apart in the market. Our business model is a strong foundation for continued future growth. As we have said many times, bronchiectasis is underdiagnosed and airway clearance is underprescribed. That said, let me turn to what I believe is the most exciting part of our story, the underserved bronchiectasis market. This represents the primary strategic opportunity for Electromed, which we are executing to capture. The numbers tell a compelling story. Today, approximately 923,000 patients in the U.S. are diagnosed with bronchiectasis, yet only 16% are currently benefiting from high-frequency chest wall oscillation therapy. Think about that.
Nearly 800,000 diagnosed patients could experience the life-changing benefits from our SmartVest system but aren't receiving this therapy today. Equally compelling is that it is estimated that over 4 million additional individuals may have undiagnosed bronchiectasis. This highlights not just a large commercial opportunity, but the need for continued education and awareness about this disease. To seize this opportunity, Electromed launched our innovative Triple Down on Bronchiectasis campaign, which promotes a powerful three-pronged treatment paradigm that's changing how clinicians think about bronchiectasis management. Number one, Clear Airways First with SmartVest to effectively remove mucus, which is the fuel for future infections. Second, treat the patient's infection with antibiotics. Third, help reduce inflammation. This approach helps break what we call the vicious vortex, where chronic infection, persistent inflammation, and damaged airways continuously worsen, leading to progressive lung disease and reduced quality of life for patients.
The campaign is delivering results. Our digital promotion of the Clear Airways First messaging has been running for 18 months and has generated over 2 million impressions and generated more than 65,000 visits to our educational landing pages. We're reaching clinicians where they are and changing the conversation around bronchiectasis treatment. At the same time, our clinical team is out in the field making a difference. In the 3rd quarter alone, they spoke at four regional respiratory conferences promoting what we call the ABCs of bronchiectasis. Always be clearing the airways first with SmartVest. We're also seeing success with peer-to-peer education. We conducted four virtual webinars featuring respected pulmonologists, which were attended by over 375 clinicians. When physicians hear from their peers about the clinical benefits of SmartVest, it moves the needle. Our presence at key conferences continues to expand our reach.
The SmartVest team attended three national conferences in the quarter, ensuring we're visible and engaged where bronchiectasis specialists gather. We've also been doing important research to understand where the gaps are in patient care. We completed a manuscript based on the data from the NTM Bronchiectasis Research Registry, which found that 58% of qualifying patients were not prescribed HFCWO therapy despite meeting clinical criteria. This gap represents an obvious opportunity for early intervention, and our team is working aggressively to close it, in part through our Sip On This campaign, aimed at driving conversations with high bronchiectasis diagnosing physicians who aren't yet prescribing HFCWO. Beyond clinical education, we're also innovating on the technology and process side to make it easier for clinicians to prescribe SmartVest and for patients to receive therapy faster. Our Smart Order ePrescribe solution is transforming how clinics submit orders to our fulfillment team.
This is particularly timely given that CMS recently finalized new rules requiring covered entities to modernize their processing of orders and phase out faxes by May 2028. Our ePrescribe solution already meets CMS requirements for electronic signatures and processing of orders, positioning us ahead of this industry shift. The introduction of the ePrescribe solution has been a success. In the third quarter, over 40% of orders came through our Smart Order solution, resulting in a five-day reduction in average days to ship versus fax orders. The number of prescriptions processed through the system is only anticipated to increase. That means patients get their therapy faster and clinics benefit from improved workflow. Increasing payer coverage remains a primary strategy to ensure patients benefit from our technology. I'm pleased to report that we now have 86% of covered lives in the U.S. under contract who could benefit from SmartVest.
The covered lives we've added over the past 18 months have resulted in over 50 referrals where we would have otherwise not been able to recognize revenue. Each one of those represents a patient whose life we can improve. On the commercial side, we ended Q3 with 58 direct sales reps. While this is flat versus the second quarter, I'm happy to report that we have since added four additional sales reps to our roster, which is now up to 62, maximizing our market coverage. Before I hand the call over to Brad, I want to touch briefly on our operational capabilities, which are yet another significant competitive advantage, especially in today's environment. Our manufacturing optimization plan initiated last year is complete. We physically restructured our manufacturing facility to improve our production process and provide capacity for future growth.
I'm particularly proud that our products are manufactured in the United States. Electromed is a U.S.-based company with operations and product assembly located domestically, and 99% of our net revenues are generated in the United States. While not without risk, we have continued to maintain our strong track record of on-time delivery to our customers and sustain our robust gross margins, even during the current uncertain global environment. With that, I'd like to turn the call over to Brad for a review of our financials. Brad, over to you.
All amounts I'm about to discuss are for the three months ended March 31st, 2026, Q3 FY 2026, and compared to the three months ended March 31st, 2025, Q3 FY 2025. Net revenues grew 18.4% to $18.6 million from $15.7 million. Revenue in the direct home care business increased by 18.6% to $16.7 million from $14.1 million. The increase in revenue was primarily due to an increase in direct sales representatives and higher net revenues per sales representative. Throughout Q3, we averaged 57 home care direct field sales representatives. The annualized home care revenue per weighted average direct sales representative in Q3 was $1,168,000, exceeding the target range of $1 million-$1.1 million for the second straight quarter.
Non-home care revenue was $1.8 million. Hospital revenue grew 42.5%, totaling $1.0 million. Home care distributor re-revenue was $0.7 million, an increase of 2.7%. Other revenue of $0.1 million declined 40.7%. Gross profit increased year-over-year to $14.6 million or 78.8% of net revenues from $12.2 million or 78.0% of net revenues. The increases in gross profit dollars and gross profit percentage were primarily a result of increased overall revenue and higher net revenues per device. Selling, general, and administrative, or SG&A expenses were $10.5 million, representing an increase of $0.7 million or 7.2%.
The increase in the current period was primarily due to increased salaries and incentive compensation related to the higher average number of sales headcount and higher overall compensation costs. Operating income was $3.8 million, or 20.3% of net revenues, compared to $2.1 million, or 13.6% of net revenues. The 76% increase in operating income was primarily due to the increases in revenue and gross profit. Net income increased by 58.8% to $3 million, or $0.35 per diluted share, compared to $1.9 million or $0.21 per diluted share.
As of March 31, 2026, Electromed had $17 million in cash, $28.3 million in accounts receivable and no debt, achieving a working capital of $40 million and total shareholders' equity of $49.2 million. The cash balance reflects an increase of $1.7 million for the nine months ended March 31, 2026, compared to a decrease in cash of $0.8 million in the nine months ended March 31, 2025. The increase in cash for the nine months ended March 31, 2026 was driven primarily by positive operating cash flow of $6.7 million, partially offset by share repurchases of $3.9 million of Electromed common stock.
While the Q3 growth rates of 18% for revenue and 76% for operating income represent recent quarterly highs rather than a new normal expectation, we remain confident in our ability to continue to deliver double-digit revenue growth, coupled with expanded operating leverage as we close out fiscal year 2026 and continue to help more patients to breathe easier into the future. With that, we'd like to move to the Q&A portion of the call. Operator, please open the call to questions.
Thank you. We will now be conducting a question and answer session. If you would like to ask a question, please press star 1 on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star 2 if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. We ask to please limit to one question and one follow-up. Your first question comes from the line of Kyle Bauser with Titan Partners. Please go ahead.
Hi, Jim and Brad. Thanks for taking my questions, and congrats on another really impressive quarter here. It sounds like a key contributor to the strong sales growth has been headcount additions, and I know there's a ramp-up period for reps, you've still managed to come in above the targeted range. Have you been adding territories or regions, or have you been splitting existing territories in half? Just kind of wondering how you've been layering in reps.
Well, Kyle, it's good to hear your voice, thanks for the question. You know, as we had indicated during our prepared remarks, we really on average had about 57 reps this past quarter. Given the strong performance, that's really attributable to really the reps that we had in territory, coupled with the fact that I think we did have some positive tailwinds relative to our insurance mix, which really, you know, helped benefit the revenue. That being said, you know, we ended the quarter with 58 reps. As I've been indicating, you know, all year, we intended to have 61 territories by the end of our fiscal year. We're now at 62 territories filled.
We're actually starting to add reps as we start to conclude Q4 and start to look at the horizon for our next fiscal year. In the next fiscal year, you know, we intend to add probably four to five additional reps, and we're on that journey right now.
Okay. Appreciate it. That was gonna be my follow-up, was kind of what is the upper bound in terms of headcount? Appreciate that. I guess, for my follow-up, do you still believe BRINSUPRI has been a net positive for SmartVest, given the increased awareness around bronchiectasis and what that's been able to do?
Yeah, we do. You know, I think the key thing for everybody on the call just to remember is that, you know, bronchiectasis is a chronic and irreversible disease. Certainly, you know, when we look at it, the drug addresses inflammation, which is part of that vicious vortex that I mentioned during the call. Fundamentally, you know, these are patients that have mucus that is building up in their airways, and they need to have something to remove that mucus, which is the future fuel for future infections. That's really where we come into play. You know, we're part of that care continuum where we're actually removing the mucus. The BRINSUPRI drug is helping to address inflammation, and that's really to stabilize the inflammation.
Certainly, the drug has been a tailwind due to increased patient and provider awareness, you know, which has been terrific, I think, and it's raised all boats that are in this market. The drug is an adjunct. It's not a replacement for SmartVest. You know, that's further validated by the fact that though the guidelines have not been published by CHEST has actually issued preliminary guidelines, and part of the care continuum is airway clearance. I think that's very promising. We're waiting for those results to be published. Those are really to help give clinicians some guidelines as to how to treat bronchiectasis patients. Heretofore, there really hasn't been any industry-wide guidelines here in the U.S. to treat bronchiectasis patients, we're excited about that.
Okay. Got it. No, that's helpful. Appreciate it. Congrats again on the results, particularly around earnings growth. I'll jump back in queue.
Thanks, Kyle.
Your next question comes from the line of Ben Haynor with Lake Street Capital Markets. Please go ahead.
Good afternoon, gentlemen. Thanks for taking the questions. First off for me, just on the new sales reps, can you kinda remind us on how quickly it typically takes to get ramped up to productivity in a new territory and whether some of these folks are entering, you know, kind of existing territories in which you've had turnover for, you know, voluntary or involuntary reasons?
Yeah. I think there's two parts to that question. Usually the ramp-up is anywhere from four-six months, Ben Hayner. We're obviously always looking in ways to collapse that timeframe, but that's a pretty good indicator of how long it takes for somebody to get their feet and, you know, get acclimated within, you know, this market and get acclimated to their new customers. When you take a look at, you know, the 61 reps that we had projected for this year, some of those were extension territories for fiscal year 2026. However, we're right now at 62 reps, as we're looking into next year, we're looking to add four to five additional territories. We're at 62 right now, and we're already on that journey. We're really excited about that.
You know, this past quarter, we did have a couple of people who actually retired, and so, you know, that's kind of a something that you can't project necessarily. Obviously, you know, we're always gonna have churn to some extent within our sales team, but we wanna make sure that our territories are filled because this still is largely a clinical sale and you need to have people in the market talking to pulmonologists, identifying patients that can benefit from our technology. We feel like our reps do just a outstanding job with that.
Okay. That's helpful. Then just, you know, considering the ABC, Always Be Closing mode, the 375 clinicians that you mentioned attending, the various events that you have, is there a way that you can kind of tell or quantify when and whether they ultimately become prescribers?
That's, I mean, we track it. A lot of it's just awareness right now. You know, part of the challenge that we haven't been able to quantify, you know, of that 375 participants that we had, in, you know, some of the peer-to-peer educational conferences, you know, what's the conversion rate on that? A lot of it is, you know, sometimes some of these clinicians, and it can be a mix of pulmonologists and other specialties, they're really getting exposed to this disease state in many cases, and the different treatment options that are out there. You know, we're helping to create that awareness in addition to the drug that has recently been introduced in the market, as well as some of our other competitors that are out there.
ATS, which is one of the large conferences for the year, is actually happening, you know, this week, that's another opportunity for us to touch really clinicians who are primarily like on the clinical side that are doing studies, et cetera. We're very excited about continuing to highlight our product technology and the difference it can make in patients' life and giving them the awareness to our product.
Excellent. That's helpful. Thanks for taking the questions, gentlemen, and congrats on the quarter.
Thank you.
There are no additional questions at this time. I would like to turn the floor back over to Jim Cunniff for closing comments.
Thank you, operator. You know, for everybody that's on the call, you know, in summary, our fiscal third quarter Electromed is firing on all cylinders. We've delivered strong financial results and executing against the largely untapped bronchiectasis opportunity with precision and purpose. Our team is focused, our strategy is working, and we have significant runway ahead of us. I wanna thank our exceptional team for their dedication, our customers for their trust, and our shareholders for their continued support. We look forward to building on our momentum in the quarters ahead. With that, thank you, everyone.
Ladies and gentlemen, thank you for your participation. This does conclude today's teleconference. You may disconnect your lines and have a wonderful day.
Investor releaseQuarter not tagged2026-05-11Electromed Inc (ELMD) Q3 2026 Earnings Report Preview: What To Look For
GuruFocus.com
Electromed Inc (ELMD) Q3 2026 Earnings Report Preview: What To Look For
This article first appeared on GuruFocus. Electromed Inc (ELMD) is set to release its Q3 2026 earnings on May 12, 2026. The consensus estimate for Q3 2026 revenue is $17.52 million, and the earnings are expected to come in at $0.24 per share. The full year 2026's revenue is expected to be $72.53 million and the earnings are expected to be $1.10 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 2 Warning Signs with BRCB. Is ELMD fairly valued? Test your thesis with our free DCF calculator. Revenue estimates for Electromed Inc (ELMD) have increased from $71.93 million to $72.53 million for the full year 2026 and increased from $80.22 million to $80.88 million for 2027 over the past 90 days. Earnings estimates for Electromed Inc (ELMD) have increased from $1.04 per share to $1.10 per share for the full year 2026 and increased from $1.27 per share to $1.33 per share for 2027 over the past 90 days. In the previous quarter of December 31, 2025, Electromed Inc's (ELMD) actual revenue was $18.90 million, which beat analysts' revenue expectations of $18.53 million by 2.01%. Electromed Inc's (ELMD) actual earnings were $0.32 per share, which beat analysts' earnings expectations of $0.26 per share by 24.51%. After releasing the results, Electromed Inc (ELMD) was down by 9.98% in one day. Based on the one-year price targets offered by 3 analysts, the average target price for Electromed Inc (ELMD) is $36.67 with a high estimate of $38.00 and a low estimate of $36.00. The average target implies an upside of 36.16% from the current price of $26.93. Based on GuruFocus estimates, the estimated GF Value for Electromed Inc (ELMD) in one year is $25.27, suggesting a downside of 6.16% from the current price of $26.93. Based on the consensus recommendation from 4 brokerage firms, Electromed Inc's (ELMD) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies strong buy, and 5 denotes sell.
Investor releaseQuarter not tagged2026-05-05IQVIA Holdings (IQV) Q1 Earnings and Revenues Beat Estimates
Zacks
IQVIA Holdings (IQV) Q1 Earnings and Revenues Beat Estimates
IQVIA Holdings (IQV) came out with quarterly earnings of $2.9 per share, beating the Zacks Consensus Estimate of $2.83 per share. This compares to earnings of $2.7 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +2.66%. A quarter ago, it was expected that this clinical testing company would post earnings of $3.4 per share when it actually produced earnings of $3.42, delivering a surprise of +0.59%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. IQVIA, which belongs to the Zacks Medical - Instruments industry, posted revenues of $4.15 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 1.62%. This compares to year-ago revenues of $3.83 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. IQVIA shares have lost about 28.6% since the beginning of the year versus the S&P 500's gain of 5.2%. While IQVIA has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for IQVIA was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here...
Investor releaseQuarter not tagged2026-04-29Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026
Business Wire
Electromed, Inc. to Report Q3 Fiscal 2026 Financial Results on May 12, 2026
NEW PRAGUE, Minn., April 28, 2026--(BUSINESS WIRE)--Electromed, Inc. ("Electromed" or the "Company") (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2026 third quarter ended March 31, 2026, on Tuesday, May 12, 2026 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing (877) 407-3982 (Toll Free) or (201) 493-6780. The live webcast of the call will be accessible in the Investor Relations section of Electromed’s website and directly via the following link: Electromed Fiscal Q3 2026 Earnings Call For those who cannot listen to the live broadcast, a replay will be available by dialing (844) 512-2921 (Toll Free) or (412) 317-6671 and referencing Access ID 13760099. Additionally, a replay of the webcast will be available in the Investor Relations section of Electromed’s web site at: Events & Presentations About Electromed, Inc. Electromed, Inc. manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest® Airway Clearance System, to patients with compromised pulmonary function. It is headquartered in New Prague, Minnesota, and was founded in 1992. Further information about Electromed can be found at www.smartvest.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260428417311/en/ Contacts Brad Nagel, Chief Financial Officer (952) 758-9299 [email protected] Mike Cavanaugh, Investor Relations ICR Healthcare (617) 877-9641 [email protected]
Investor releaseQuarter not tagged2026-03-04Electromed (ELMD) Reports 13th Consecutive Quarter of Revenue and Profit Growth
Insider Monkey
Electromed (ELMD) Reports 13th Consecutive Quarter of Revenue and Profit Growth
Electromed Inc. (NYSEAMERICAN:ELMD) is one of the most promising micro-cap stocks according to analysts. On February 10, Electromed achieved its 13th consecutive quarter of year-over-year revenue and profit growth, reporting record net revenues of $18.9 million for FQ2 2026. This 16.3% increase was primarily driven by the company’s core home care business, which grew 18.4% to $17.3 million. This surge was supported by a highly productive sales force that averaged $1.2 million in annualized revenue per representative, exceeding the company’s target range. Additionally, the launch of Brensupri, the first FDA-approved drug for bronchiectasis, has heightened market awareness, complementing the use of Electromed’s SmartVest system. The company’s focus on operational execution led to a record operating income of $3.6 million, a 42.4% increase over the previous year. Net income also hit a record $2.8 million, resulting in earnings per share of $0.32. Photographee.eu/Shutterstock.com Management at Electromed Inc. (NYSEAMERICAN:ELMD) remains focused on closing the treatment gap for the 58% of qualifying patients who do not yet receive HFCWO therapy, supported by the execution of 25 new payer contracts that added 2.9 million covered lives to their potential patient base. Electromed Inc. (NYSEAMERICAN:ELMD) develops, manufactures, markets, and sells airway clearance therapy and related products that apply high-frequency chest wall oscillation/HFCWO therapy in pulmonary care for patients in the US and internationally. While we acknowledge the potential of ELMD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Small Cap Tech Stocks With High Upside Potential. Disclosure: None. Follow Insider Monkey on Google News.
Investor releaseQuarter not tagged2026-02-13Electromed Inc (ELMD) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth ...
GuruFocus.com
Electromed Inc (ELMD) Q2 2026 Earnings Call Highlights: Record Revenue and Strategic Growth ...
This article first appeared on GuruFocus. Revenue: $18.9 million, a 16.3% year-over-year increase. Home Care Business Revenue: $17.3 million, an 18.4% year-over-year increase. Distributor Channel Revenue: 12.1% year-over-year increase. Hospital Channel Revenue: 9.4% year-over-year decline. Operating Income: $3.6 million, a 42.4% year-over-year increase, representing 19% of sales. Earnings Per Share (EPS): $0.32, up from $0.22 in the previous year. Gross Profit: $14.8 million, 78.4% of net revenues. SG&A Expenses: $10.8 million, a 10% increase. Net Income: $2.8 million, a 40.3% year-over-year increase. Cash on Hand: $13.8 million, with no debt. Working Capital: $36.2 million. Total Shareholders' Equity: $45.4 million. Cash Flow: $3.2 million positive operating cash flow, offset by $3.8 million in share repurchases. Warning! GuruFocus has detected 1 Warning Sign with NSE:GICRE. Is ELMD fairly valued? Test your thesis with our free DCF calculator. Release Date: February 10, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Electromed Inc (ELMD) achieved its 13th consecutive quarter of year-over-year revenue and profit growth, highlighting the strength of its business model. The company reported record revenue of $18.9 million for fiscal Q2, representing a robust 16.3% year-over-year growth. Operating income grew by 42.4% year-over-year, reaching $3.6 million, with operating income as a percentage of sales at an impressive 19%. Electromed Inc (ELMD) maintains a strong balance sheet with $13.8 million in cash and no debt, reflecting financial stability. The company executed 25 payer contracts, adding $2.9 million covered lives, expanding its market reach and potential patient base. The hospital channel experienced a 9.4% year-over-year decline in revenue due to strategic prioritization and unpredictable timing of capital orders. Non-home care revenue decreased, with hospital revenue down 9.4% and other revenue declining by 52.3%. The cash balance decreased by $1.5 million over six months, driven by share repurchases, despite positive operating cash flow. There is a significant gap in the market, with 58% of qualifying patients not receiving HFCWO therapy despite meeting clinical criteria. The expansion of sales representatives may lead to a temporary decline in productivity per rep as new hires require train...
Investor releaseQuarter not tagged2026-02-11Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates
Zacks
Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +20.76%. A quarter ago, it was expected that this company would post earnings of $0.22 per share when it actually produced earnings of $0.25, delivering a surprise of +13.64%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Electromed, which belongs to the Zacks Medical - Instruments industry, posted revenues of $18.9 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.40%. This compares to year-ago revenues of $16.25 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Electromed shares have lost about 5.2% since the beginning of the year versus the S&P 500's gain of 1.7%. While Electromed has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Electromed was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong...
Investor releaseQuarter not tagged2026-02-11Electromed, Inc. Q2 2026 Earnings Call Summary
Moby
Electromed, Inc. Q2 2026 Earnings Call Summary
Achieved record revenue growth of 16.3% driven by an 18.4% surge in the core Home Care business and increased sales force productivity. Attributed strong performance to the 'Triple Down on Bronchiectasis' campaign, which promotes a three-pronged treatment paradigm of airway clearance, infection treatment, and inflammation reduction. Prioritized shipments to high-demand home patients over the hospital channel, resulting in a temporary 9.4% decline in hospital revenue due to strategic allocation and unpredictable capital order timing. Leveraged a US-based manufacturing footprint to maintain mid-70% gross margins and mitigate potential supply chain risks associated with international tariffs. Expanded market access by executing 25 new payer contracts in the first half of the fiscal year, adding 2.9 million covered lives to the existing 270 million under contract. Improved operational efficiency through the Smart Order e-prescribe solution, which now handles over one-third of total orders, replacing legacy fax-based processes. Enhanced field sales productivity and market insights via the successful implementation of a new CRM system and manufacturing optimization plan. Plans to expand the direct sales force from 58 to 61 representatives by the end of the fiscal year to increase market reach. Expects sales representative productivity to normalize within the target range of $1 million to $1.1 million as new hires are onboarded and trained. Anticipates a rebound in hospital channel demand in coming quarters following the strategic prioritization of home care patients in Q2. Aims to maintain double-digit top-line growth and expanded operating leverage throughout the remainder of fiscal year 2026. Focuses on closing the treatment gap for the 58% of qualifying bronchiectasis patients who are currently not prescribed HFCWO therapy despite meeting clinical criteria. Board authorized a $10 million stock repurchase program in Q1, with $3.8 million already executed in the first half of the fiscal year. Management remains vigilant regarding upstream tariff exposure within domestic supply chains, though US-centric assembly provides a competitive buffer. Maintains a debt-free balance sheet with $13.8 million in cash to support opportunistic capital allocation and growth investments. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you...